Clinical Trials Browser

Interventional × Uterine Cervical Neoplasms × Cisplatin × Clear all

NCT02466971 2026-04-13

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

Phase 3 Active not recruiting

450 enrolled 11 charts

Uterine Cervical Neoplasms, Vaginal Neoplasms

NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

Phase 1 Active not recruiting

BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

NCT07216703 2026-04-09

TroFuse-036

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT05570422 2026-04-08

A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01

Phase 1 Recruiting

Uterine Cervical Neoplasms

NCT04389632 2026-04-07

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Phase 1 Recruiting

GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT07276360 2026-03-27

HypoRTCx-UG

Phase 2 Recruiting

Uterine Cervical Neoplasms

NCT06535607 2026-03-24

eVOLVE-02

Phase 2 Recruiting

GastrointestinalGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Uterine Cervical Neoplasms

NCT00421096 2026-03-13

GEMCOL

Phase 2 Terminated

Uterine Cervical Neoplasms

NCT05521997 2026-03-13

Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

Phase 2 Not yet recruiting

Uterine Cervical Neoplasms

NCT03256916 2026-02-24

NELCER

Phase 3 Completed

Uterine Cervical Neoplasms

NCT04221945 2026-02-20

KEYNOTE-A18

Phase 3 Completed

1,060 enrolled 30 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT03635567 2026-02-04

KEYNOTE-826

Phase 3 Completed

617 enrolled 29 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT00980954 2025-12-31

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Phase 3 Completed

236 enrolled 28 charts

Uterine Cervical Neoplasms

NCT06331468 2025-12-26

Hypofractionated Radiochemotherapy

Phase 2 Recruiting

Uterine Cervical Neoplasms, Uterine Neoplasms

NCT07232654 2025-12-01

Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC

Phase 2 Recruiting

Uterine Cervical Neoplasms

NCT00957411 2025-11-24

CETUXICOL

Phase 2 Completed

Uterine Cervical Neoplasms

NCT07244965 2025-11-24

Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer

Phase 2 Not yet recruiting

Uterine Cervical Neoplasms

NCT04982237 2025-11-19

A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Phase 3 Active not recruiting

Uterine Cervical Neoplasms

NCT02595879 2025-11-13

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer

Phase 1 Active not recruiting

21 enrolled 22 charts

Uterine Cervical Neoplasms

NCT03738228 2025-11-12

Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer

Phase 1 Completed

40 enrolled 17 charts

Uterine Cervical Neoplasms

NCT07088731 2025-09-22

Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer

Phase 2 Not yet recruiting

Uterine Cervical Neoplasms

NCT03298893 2025-09-19

NiCOL

Phase 1/2 Completed

Uterine Cervical Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT04016389 2025-08-12

FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

Phase NA Recruiting

Uterine Cervical Neoplasms

NCT03086681 2025-07-29

ECWHCCFLACC

Phase 2 Completed

Uterine Cervical Neoplasms

NCT02635360 2025-07-03

Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer

Phase 2 Completed

94 enrolled 16 charts

Uterine Cervical Neoplasms

NCT06859775 2025-06-06

SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

Phase 1/2 Recruiting

Uterine Cervical Neoplasms, Recurrence

NCT01101451 2025-05-23

Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

Phase 3 Completed

340 enrolled 13 charts

Uterine Cervical Neoplasms

NCT03255252 2025-05-18

IMMUVIX

Phase 2 Terminated

Uterine Cervical Neoplasms

NCT06942416 2025-04-24

Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer

Phase 2 Recruiting

Uterine Cervical Neoplasms, Neoplasm Recurrence, Local, Neoplasms

NCT05179239 2025-04-15

A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer

Phase 3 Terminated

Uterine Cervical Neoplasms

NCT05857631 2025-04-15

PARCERII

Phase NA Recruiting

Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT03527264 2025-04-04

BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer

Phase 2 Terminated

4 enrolled 11 charts

Uterine Cervical Neoplasms

NCT06558682 2025-04-01

Neoadjuvant Therapy in Cervical Cancer

Phase NA Recruiting

Uterine Cervical Neoplasms

NCT06786780 2025-03-26

ECCO

Phase 2 Enrolling by invitation

Uterine Cervical Neoplasms

NCT06288360 2025-03-20

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Phase 2 Recruiting

Uterine Cervical Neoplasms

NCT04868708 2025-03-04

A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

Phase 2 Completed

Diabetes Mellitus, Insulin-Dependent, 12, Uterine Cervical Neoplasms, Recurrence

NCT06123884 2025-02-10

BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer

Phase 2/3 Recruiting

Uterine Cervical Neoplasms

NCT04275713 2025-01-20

METOXY-LACC

Phase 2 Completed

Uterine Cervical Neoplasms

NCT03556839 2025-01-08

BEATcc

Phase 3 Active not recruiting

Carcinoma, Uterine Cervical Neoplasms

NCT06755515 2025-01-01

A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Phase 2/3 Enrolling by invitation

Uterine Cervical Neoplasms

NCT01566240 2024-12-05

INTERLACE

Phase 3 Active not recruiting

Uterine Cervical Neoplasms

NCT01554397 2024-11-29

Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer

Phase 2/3 Completed

101 enrolled 13 charts

Carcinoma, Uterine Cervical Neoplasms

NCT06289062 2024-11-05

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

Phase 2 Recruiting

Uterine Cervical Neoplasms

NCT04723875 2024-11-01

Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline

Phase 3 Active not recruiting

Uterine Cervical Neoplasms

NCT06288373 2024-10-30

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

Phase 2/3 Recruiting

Uterine Cervical Neoplasms

NCT06289751 2024-09-19

Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer

Phase 2 Recruiting

Uterine Cervical Neoplasms

NCT05764044 2024-07-30

AddChemo

Phase 3 Recruiting

Uterine Cervical Neoplasms

NCT03367871 2024-06-18

Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer

Phase 2 Terminated

17 enrolled 12 charts

Uterine Cervical Neoplasms

NCT06426056 2024-05-23

Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial.

Phase 2 Not yet recruiting

Uterine Cervical Neoplasms